COX-2, VEGF and tumour angiogenesis

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidemiological studies indicate a protective effect of regular NSAID use against cancer development.
• Cyclooxygenase-2 (COX-2), a key target of NSAIDs, is frequently upregulated in various cancers.
• COX-2 is implicated in promoting tumor growth through increased vascular endothelial growth factor (VEGF) production and angiogenesis.

Purpose of the Study:

• To review the current understanding of COX-2's role in tumorigenesis.
• To focus on the relationship between COX-2, VEGF production, and angiogenesis in tumor cells.
• To evaluate the therapeutic potential of targeting COX-2 in cancer treatment.

Main Methods:

• Extensive literature review.
• Analysis of epidemiological evidence on NSAID use and cancer.
• Examination of molecular mechanisms linking COX-2 to VEGF and angiogenesis.

Main Results:

• COX-2 upregulation is associated with increased VEGF production and angiogenesis in tumors.
• Tumor angiogenesis, essential for tumor development, is a significant therapeutic target.
• While COX-2 appears detrimental to prognosis, NSAIDs show a beneficial effect.

Conclusions:

• COX-2 plays a significant role in tumorigenesis, particularly through its influence on angiogenesis and VEGF.
• NSAIDs demonstrate a beneficial effect in cancer, likely mediated partly by COX-2 inhibition.
• The possibility of COX-2-independent mechanisms contributing to NSAID's protective effects cannot be ruled out.